Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $169 from $175 and keeps a Neutral rating on the shares. The firm said discrete customer decisions to defer ramps on new product intros, combined with capital goods demand softnes at year-end 2024 all contributing to revisions.